Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial

Research output: Contribution to journalArticle


  • T Eisen
  • S Oudard
  • C Szczylik
  • G Gravis
  • H Heinzer
  • R Middleton
  • F Cihon
  • S Anderson
  • S Shah
  • R Bukowski
  • B Escudier
  • Emilio Porfiri
  • Target Study group

Colleges, School and Institutes


BACKGROUND: The perception that older cancer patients may be at higher risk than younger patients of toxic effects from cancer therapy but may obtain less clinical benefit from it may be based on the underrepresentation of older patients in clinical trials and the known toxic effects of cytotoxic chemotherapy. It is not known how older patients respond to targeted therapy. METHODS: This retrospective subgroup analysis of data from the phase 3, randomized Treatment Approach in Renal Cancer Global Evaluation Trial examined the safety and efficacy of sorafenib in older (age >or=70 years, n = 115) and younger patients (age or=70 years) and younger (


Original languageEnglish
Pages (from-to)1454-63
Number of pages10
JournalJournal of the National Cancer Institute
Issue number20
Publication statusPublished - 15 Oct 2008